Allergan Lumigan Unsubstantiated Superiority Claims Cited In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company must send corrective messages regarding the violative sales aid for Lumigan that contains misleading claims regarding the superiority of the ocular therapy, FDA says.
You may also be interested in...
Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says
Inspire Pharmaceuticals gets a letter from FDA's Division of Drug Marketing, Advertising and Communications for a four-page professional journal ad for its bacterial conjunctivitis treatment AzaSite.
Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says
Inspire Pharmaceuticals gets a letter from FDA's Division of Drug Marketing, Advertising and Communications for a four-page professional journal ad for its bacterial conjunctivitis treatment AzaSite.
FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.